难治性糖尿病性黄斑水肿的治疗进展  

Advances in Treatment of Refractory Diabetic Macular Edema

作　　者：刘洋 陈颖欣 LIU Yang;CHEN Yingxin(Graduate School of Dalian Medical University,Dalian 116044,China;Department of Ophthalmology,General Hospital of the Northern Theater of Operations,Shenyang 110000,China)

机构地区：[1]大连医科大学研究生院,辽宁大连116044 [2]北部战区总医院眼科,沈阳110000

出　　处：《医学综述》2025年第3期334-338,344,共6页Medical Recapitulate

摘　　要：糖尿病性黄斑水肿(DME)作为糖尿病视网膜病变患者的主要并发症之一,是导致患者视力下降的主要原因。目前,血管内皮生长因子(VEGF)抑制剂广泛应用于DME的治疗且疗效显著,但仍有部分患者经过多次抗VEGF治疗后水肿未见消退或反复发生,出现对抗VEGF无应答或应答不佳的难治性DME。现阶段针对难治性DME的治疗并无明确指南,治疗方法包括激光、类固醇皮质激素、抗VEGF药物的转换、手术及联合治疗。未来研究应着眼于探索更多治疗方法,以为难治性DME的有效治疗提供参考。Diabetic macular edema(DME),as one of the major complications in patients with diabetic retinopathy,is the main cause of vision loss.Currently,vascular endothelial growth factor(VEGF)inhibitors are widely used in the treatment of DME with remarkable efficacy,but there are still some patients with refractory DME who have no or poor response to anti-VEGF,as the edema does not subside or recurs after multiple anti-VEGF treatments.At this stage,there is no clear guideline on the treatment of refractory DME,and the treatment options include laser,corticosteroids,switching anti-VEGF drugs,surgery and combination therapy.Future researchers should focus on exploring more treatment methods to provide references for effective treatment for refractory DME.

关 键 词：糖尿病性黄斑水肿 糖尿病视网膜病变 血管内皮生长因子 类固醇皮质激素 

分 类 号：R774.5[医药卫生—眼科]